Jakarta, CNN Indonesia —
These results were obtained after Pfizer performed tests on 2,228 adolescents. There were 30 symptomatic Covid-19 cases among all participants. All were in the placebo group. Meanwhile, no symptomatic Covid-19 cases have been found from the group of vaccine recipients.
The researchers concluded that the vaccine’s effectiveness was consistently high for gender, race, obesity, and comorbidity status.
“As the global health community seeks to increase the number of people vaccinated around the world, this additional data provides further credibility in the safety and efficacy profile of our adolescent vaccines,” said Albert Bourla, CEO of Pfizer.
In addition, Pfizer did not find any serious problems in people who received two doses of the vaccine after a six-month follow-up.
This finding is important, according to Bourla, considering that the prevalence of Covid-19 in the adolescent age group is increasing in a number of countries around the world.
“This is especially important as Covid-19 rates in this age group are increasing in some regions as vaccine uptake slows down. We look forward to sharing this data with the FDA and other regulatory agencies, ”said Bourla.